{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:57:54Z","timestamp":1780779474786,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11916-022-01070-6","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T10:03:08Z","timestamp":1658829788000},"page":"667-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache"],"prefix":"10.1007","volume":"26","author":[{"given":"Shu-Ting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0952-9608","authenticated-orcid":false,"given":"Jr-Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"1070_CR1","doi-asserted-by":"crossref","unstructured":"\u2022\u00a0May A, Schwedt TJ, Magis D, Pozo-Rosich P, Evers S, Wang SJ. Cluster headache. Nat Rev Dis Primers. 2018;4:18006.\u00a01.\u00a0This article provides a comprehensive review of the clinical presentations, pathophysiology, and treatments for cluster headache.","DOI":"10.1038\/nrdp.2018.6"},{"key":"1070_CR2","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/j.1526-4610.2006.00534.x","volume":"46","author":"M Schurks","year":"2006","unstructured":"Schurks M, Kurth T, de Jesus J, Jonjic M, Rosskopf D, Diener HC. Cluster headache: clinical presentation, lifestyle features, and medical treatment. Headache. 2006;46:1246\u201354.","journal-title":"Headache"},{"key":"1070_CR3","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"1070_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10194-005-0142-9","volume":"6","author":"I Favier","year":"2005","unstructured":"Favier I, Haan J, Ferrari MD. Chronic cluster headache: a review. J Headache Pain. 2005;6:3\u20139.","journal-title":"J Headache Pain"},{"key":"1070_CR5","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1136\/jnnp.2006.112037","volume":"78","author":"A Donnet","year":"2007","unstructured":"Donnet A, Lanteri-Minet M, Guegan-Massardier E, Mick G, Fabre N, G\u00e9raud G, et al. Chronic cluster headache: a French clinical descriptive study. J Neurol Neurosurg Psychiatry. 2007;78:1354\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1070_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1468-2982.1991.1104169.x","volume":"11","author":"GC Manzoni","year":"1991","unstructured":"Manzoni GC, Micieli G, Granella F, Tassorelli C, Zanferrari C, Cavallini A. Cluster headache\u2014course over ten years in 189 patients. Cephalalgia. 1991;11:169\u201374.","journal-title":"Cephalalgia"},{"key":"1070_CR7","doi-asserted-by":"crossref","unstructured":"Ko C-A, Lin G-Y, Ting C-H, Sung Y-F, Lee J-T, Tsai C-K, et al. Clinical features of cluster headache: a hospital-based study in Taiwan. Front Neurol. 2021;12.","DOI":"10.3389\/fneur.2021.636888"},{"key":"1070_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1468-2982.2003.00721.x","volume":"24","author":"KH Lin","year":"2004","unstructured":"Lin KH, Wang PJ, Fuh JL, Lu SR, Chung CT, Tsou HK, et al. Cluster headache in the Taiwanese \u2014 a clinic-based study. Cephalalgia. 2004;24:631\u20138.","journal-title":"Cephalalgia"},{"key":"1070_CR9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1177\/0333102410391486","volume":"31","author":"N Imai","year":"2011","unstructured":"Imai N, Yagi N, Kuroda R, Konishi T, Serizawa M, Kobari M. Clinical profile of cluster headaches in Japan: low prevalence of chronic cluster headache, and uncoupling of sense and behaviour of restlessness. Cephalalgia. 2011;31:628\u201333.","journal-title":"Cephalalgia"},{"key":"1070_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/practneurol-2018-002124","volume":"19","author":"DY Wei","year":"2019","unstructured":"Wei DY, Khalil M, Goadsby PJ. Managing cluster headache. Pract Neurol. 2019;19:521\u20138.","journal-title":"Pract Neurol"},{"key":"1070_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1474-4422(20)30363-X","volume":"20","author":"M Obermann","year":"2021","unstructured":"Obermann M, N\u00e4gel S, Ose C, Sonuc N, Scherag A, Storch P, et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. Lancet Neurol. 2021;20:29\u201337.","journal-title":"Lancet Neurol"},{"key":"1070_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1129-2377-15-79","volume":"15","author":"DD Mitsikostas","year":"2014","unstructured":"Mitsikostas DD, Edvinsson L, Jensen RH, Katsarava Z, Lampl C, Negro A, et al. Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. 2014;15:79.","journal-title":"J Headache Pain"},{"issue":"Suppl 2","key":"1070_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/head.13583","volume":"59","author":"H Yuan","year":"2019","unstructured":"Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache. 2019;59(Suppl 2):20\u201332.","journal-title":"Headache"},{"key":"1070_CR14","doi-asserted-by":"crossref","unstructured":"Cohen F, Yuan H, Silberstein SD. Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs. 2022.","DOI":"10.1007\/s40259-022-00530-0"},{"issue":"4","key":"1070_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/jnnp-2014-308122","volume":"86","author":"F-C Yang","year":"2015","unstructured":"Yang F-C, Chou K-H, Fuh J-L, Lee P-L, Lirng J-F, Lin Y-Y, et al. Altered hypothalamic functional connectivity in cluster headache: a longitudinal resting-state functional MRI study. J Neurol Neurosurg Psychiatry. 2015;86(4):437\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1070_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s10194-020-01098-2","volume":"21","author":"LH Schulte","year":"2020","unstructured":"Schulte LH, Haji AA, May A. Phase dependent hypothalamic activation following trigeminal input in cluster headache. J Headache Pain. 2020;21:30.","journal-title":"J Headache Pain"},{"key":"1070_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1186\/s10194-015-0562-0","volume":"16","author":"MC Barloese","year":"2015","unstructured":"Barloese MC. Neurobiology and sleep disorders in cluster headache. J Headache Pain. 2015;16:562.","journal-title":"J Headache Pain"},{"key":"1070_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/JPR.S175312","volume":"12","author":"A Buture","year":"2019","unstructured":"Buture A, Boland JW, Dikomitis L, Ahmed F. Update on the pathophysiology of cluster headache: imaging and neuropeptide studies. J Pain Res. 2019;12:269\u201381.","journal-title":"J Pain Res"},{"key":"1070_CR19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/j.1468-2982.2007.01386.x","volume":"27","author":"T Sprenger","year":"2007","unstructured":"Sprenger T, Ruether KV, Boecker H, Valet M, Berthele A, Pfaffenrath V, et al. Altered metabolism in frontal brain circuits in cluster headache. Cephalalgia. 2007;27:1033\u201342.","journal-title":"Cephalalgia"},{"key":"1070_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.pain.2013.02.005","volume":"154","author":"FC Yang","year":"2013","unstructured":"Yang FC, Chou KH, Fuh JL, Huang CC, Lirng JF, Lin YY, et al. Altered gray matter volume in the frontal pain modulation network in patients with cluster headache. Pain. 2013;154:801\u20137.","journal-title":"Pain"},{"key":"1070_CR21","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1177\/0333102417738252","volume":"38","author":"PJ Goadsby","year":"2018","unstructured":"Goadsby PJ. Cluster headache and the trigeminal-autonomic reflex: Driving or being driven? Cephalalgia. 2018;38:1415\u20137.","journal-title":"Cephalalgia"},{"key":"1070_CR22","doi-asserted-by":"crossref","unstructured":"Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622\u2013651.","DOI":"10.2165\/00003495-199447040-00006"},{"key":"1070_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/j.1468-2982.2008.01675.x","volume":"28","author":"L Edvinsson","year":"2008","unstructured":"Edvinsson L, Tfelt-Hansen P. The blood-brain barrier in migraine treatment. Cephalalgia. 2008;28:1245\u201358.","journal-title":"Cephalalgia"},{"key":"1070_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0304-3959(94)00097-X","volume":"60","author":"M Fanciullacci","year":"1995","unstructured":"Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 1995;60:119\u201323.","journal-title":"Pain"},{"key":"1070_CR25","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117:427\u2013434.","DOI":"10.1093\/brain\/117.3.427"},{"key":"1070_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0333102420949858","volume":"41","author":"K Kamm","year":"2021","unstructured":"Kamm K, Straube A, Ruscheweyh R. Baseline tear fluid CGRP is elevated in active cluster headache patients as long as they have not taken attack abortive medication. Cephalalgia. 2021;41:69\u201377.","journal-title":"Cephalalgia"},{"key":"1070_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-016-0660-7","volume":"17","author":"B Tuka","year":"2016","unstructured":"Tuka B, Szab\u00f3 N, T\u00f3th E, Kincses ZT, P\u00e1rdutz \u00c1, Szok D, et al. Release of PACAP-38 in episodic cluster headache patients \u2014 an exploratory study. J Headache Pain. 2016;17:69\u201369.","journal-title":"J Headache Pain"},{"key":"1070_CR28","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117(Pt 3):427\u2013434.","DOI":"10.1093\/brain\/117.3.427"},{"key":"1070_CR29","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/acn3.113","volume":"1","author":"AS Zagami","year":"2014","unstructured":"Zagami AS, Edvinsson L, Goadsby PJ. Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol. 2014;1:1036\u201340.","journal-title":"Ann Clin Transl Neurol"},{"key":"1070_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-017-0821-3","volume":"18","author":"H Ashina","year":"2017","unstructured":"Ashina H, Guo S, Vollesen ALH, Ashina M. PACAP38 in human models of primary headaches. J Headache Pain. 2017;18:110\u2013110.","journal-title":"J Headache Pain"},{"key":"1070_CR31","doi-asserted-by":"crossref","unstructured":"\u2022\u00a0Vollesen ALH, Snoer A, Beske RP, Guo S, Hoffmann J, Jensen RH, et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol. 2018;75:1187\u20131197.\u00a0This infusion study found CGRP infusion less commonly triggered CH attacks in chronic (50%) than episodic cluster headache patients (89%), suggesting differences in CGRP sensitivity between episodic and chronic cluster headache patients.","DOI":"10.1001\/jamaneurol.2018.1675"},{"key":"1070_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/0333102419837154","volume":"39","author":"A Snoer","year":"2019","unstructured":"Snoer A, Vollesen ALH, Beske RP, Guo S, Hoffmann J, Fahrenkrug J, et al. Calcitonin-gene related peptide and disease activity in cluster headache. Cephalalgia. 2019;39:575\u201384.","journal-title":"Cephalalgia"},{"key":"1070_CR33","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1177\/0333102420940689","volume":"40","author":"ALH Vollesen","year":"2020","unstructured":"Vollesen ALH, Snoer A, Chaudhry B, Petersen AS, Hagedorn A, Hoffmann J, et al. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache. Cephalalgia. 2020;40:1474\u201388.","journal-title":"Cephalalgia"},{"key":"1070_CR34","unstructured":"Pellesi L, Chaudhry BA, Vollesen ALH, Snoer AH, Baumann K, Skov PS, et al. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. Cephalalgia. 0:03331024211056248."},{"key":"1070_CR35","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442\u201354.","journal-title":"Cephalalgia"},{"key":"1070_CR36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75:1080\u20138.","journal-title":"JAMA Neurol"},{"key":"1070_CR37","first-page":"e2211","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine. The randomized, double-blind, placebo-controlled REGAIN study. 2018;91:e2211\u201321.","journal-title":"The randomized, double-blind, placebo-controlled REGAIN study"},{"key":"1070_CR38","doi-asserted-by":"crossref","unstructured":"\u2022\u00a0Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381:132\u2013141.\u00a0This manuscript demonstrates the efficacy of galcanezumab for the preventive treatment of episodic cluster headache.","DOI":"10.1056\/NEJMoa1813440"},{"key":"1070_CR39","doi-asserted-by":"publisher","first-page":"251581632110156","DOI":"10.1177\/25158163211015654","volume":"4","author":"B Plato","year":"2021","unstructured":"Plato B, Andrews JS, Rettiganti M, Tockhorn-Heidenreich A, Bardos J, Wenzel R, et al. Efficacy of galcanezumab in patients with episodic cluster headaches and a history of preventive treatment failure. Cephalalgia Reports. 2021;4:25158163211015656.","journal-title":"Cephalalgia Reports"},{"key":"1070_CR40","doi-asserted-by":"crossref","unstructured":"\u2022\u00a0Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia. 2020;40:935\u2013948.\u00a0This paper found that galcanezumab is ineffective for the preventive treatment of chronic cluster headaches.","DOI":"10.1177\/0333102420905321"},{"key":"1070_CR41","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1212\/WNL.94.15_supplement.4023","volume":"94","author":"M Lanteri-Minet","year":"2020","unstructured":"Lanteri-Minet M, Kalidas K, Oakes TM, Bardos J, Zhou C, Wenzel R, et al. Acute and preventive treatment use in a phase 3 randomized trial of galcanezumab in chronic cluster headache (4023). Neurology. 2020;94:4023.","journal-title":"Neurology"},{"key":"1070_CR42","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999\u20132008.","journal-title":"JAMA"},{"key":"1070_CR43","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113\u201322.","journal-title":"N Engl J Med"},{"key":"1070_CR44","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030\u201340.","journal-title":"Lancet"},{"key":"1070_CR45","unstructured":"\u2022 Lipton RB, Diener HC, Barbanti P, Schiemann J, Barash S, Cohen JM, et al. Efficacy and safety of fremanezumab for the prevention of episodic cluster headache: results of a randomized, double-blind, placebo controlled, phase 3 study. Cephalalgia. 2019;39:358\u20139.\u00a0This abstract from the Internation Headache Congress 2019 showed that fremanezumab is ineffective for the preventive treatment of episodic\u00a0cluster headache."},{"key":"1070_CR46","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/14712598.2020.1751114","volume":"20","author":"C Chan","year":"2020","unstructured":"Chan C, Goadsby PJ. CGRP pathway monoclonal antibodies for cluster headache. Expert Opin Biol Ther. 2020;20:947\u201353.","journal-title":"Expert Opin Biol Ther"},{"key":"1070_CR47","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123\u201332.","journal-title":"N Engl J Med"},{"key":"1070_CR48","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1177\/03331024211024160","volume":"41","author":"SJ Wang","year":"2021","unstructured":"Wang SJ, Roxas AA Jr, Saravia B, Kim BK, Chowdhury D, Riachi N, et al. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia. 2021;41:1285\u201397.","journal-title":"Cephalalgia"},{"key":"1070_CR49","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/head.13832","volume":"60","author":"M Silvestro","year":"2020","unstructured":"Silvestro M, Tessitore A. Scotto di Clemente F, Tedeschi G, Russo A: Erenumab Efficacy on comorbid cluster headache in patients with migraine: a real-world case series. Headache. 2020;60:1187\u201395.","journal-title":"Headache"},{"key":"1070_CR50","doi-asserted-by":"publisher","first-page":"251581632094771","DOI":"10.1177\/2515816320947713","volume":"3","author":"F Riederer","year":"2020","unstructured":"Riederer F, Wenner AM. Erenumab for chronic cluster headache: a case report. Cephalalgia Reports. 2020;3:2515816320947713.","journal-title":"Cephalalgia Reports"},{"key":"1070_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241\u201354.","journal-title":"Cephalalgia"},{"key":"1070_CR52","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94:e1365\u201377.","journal-title":"Neurology"},{"key":"1070_CR53","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0333102420949866","volume":"40","author":"R Ruscheweyh","year":"2020","unstructured":"Ruscheweyh R, Broessner G, Go\u00dfrau G, Heinze-Kuhn K, J\u00fcrgens TP, Kaltseis K, et al. Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: results from a retrospective case series support individual treatment attempts. Cephalalgia. 2020;40:1574\u201384.","journal-title":"Cephalalgia"},{"key":"1070_CR54","doi-asserted-by":"crossref","unstructured":"Tepper D. Gepants. Headache: J Head Face Pain. 2020;60:1037\u20131039.","DOI":"10.1111\/head.13791"},{"key":"1070_CR55","first-page":"686","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials. ACHIEVE I and II Headache. 2020;60:686\u2013700.","journal-title":"ACHIEVE I and II Headache"},{"key":"1070_CR56","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394:737\u201345.","journal-title":"Lancet"},{"key":"1070_CR57","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2147\/JPR.S244249","volume":"14","author":"CC Chiang","year":"2021","unstructured":"Chiang CC, VanderPluym JH. Ubrogepant in the acute management of migraine: a narrative review. J Pain Res. 2021;14:1185\u201392.","journal-title":"J Pain Res"},{"key":"1070_CR58","first-page":"713","volume":"325","author":"A Slomski","year":"2021","unstructured":"Slomski A. Oral Rimegepant Safe, Effective for migraine prevention. JAMA. 2021;325:713\u2013713.","journal-title":"JAMA"},{"key":"1070_CR59","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695\u2013706.","journal-title":"N Engl J Med"},{"key":"1070_CR60","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1046\/j.1468-29821995.1506452.x","volume":"15","author":"RB Lipton","year":"1995","unstructured":"Lipton RB, Micieli G, Russell D, Solomon S, Tfelt-Hansen P, Waldenlind E. Guidelines for controlled trials of drugs in cluster headache. Cephalalgia. 1995;15:452\u201362.","journal-title":"Cephalalgia"},{"key":"1070_CR61","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/head.14292","volume":"62","author":"DW Dodick","year":"2022","unstructured":"Dodick DW, Goadsby PJ, Ashina M, Tassorelli C, Hundemer HP, Bardos JN, et al. Challenges and complexities in designing cluster headache prevention clinical trials: a narrative review. Headache. 2022;62:453\u201372.","journal-title":"Headache"},{"key":"1070_CR62","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1526-4610.1990.hed3007411.x","volume":"30","author":"G Bussone","year":"1990","unstructured":"Bussone G, Leone M, Peccarisi C, Micieli G, Granella F, Magri M, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache. 1990;30:411\u20137.","journal-title":"Headache"},{"key":"1070_CR63","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1046\/j.1468-2982.1997.1706673.x","volume":"17","author":"TJ Steiner","year":"1997","unstructured":"Steiner TJ, Hering R, Couturier EG, Davies PT, Whitmarsh TE. Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia. 1997;17:673\u20135.","journal-title":"Cephalalgia"},{"key":"1070_CR64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/head.13730","volume":"60","author":"MCJ Barloese","year":"2020","unstructured":"Barloese MCJ, Beske RP, Petersen AS, Haddock B, Lund N, Jensen RH. Episodic and chronic cluster headache: differences in family history, traumatic head injury, and chronorisk. Headache. 2020;60:515\u201325.","journal-title":"Headache"},{"key":"1070_CR65","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1177\/0333102418769955","volume":"38","author":"M Barloese","year":"2018","unstructured":"Barloese M, Haddock B, Lund NT, Petersen A, Jensen R. Chronorisk in cluster headache: a tool for individualised therapy? Cephalalgia. 2018;38:2058\u201367.","journal-title":"Cephalalgia"},{"key":"1070_CR66","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11916-014-0415-6","volume":"18","author":"S Naegel","year":"2014","unstructured":"Naegel S, Holle D, Obermann M. Structural imaging in cluster headache. Curr Pain Headache Rep. 2014;18:415.","journal-title":"Curr Pain Headache Rep"},{"key":"1070_CR67","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/13543784.2020.1811966","volume":"29","author":"C Rustichelli","year":"2020","unstructured":"Rustichelli C, Lo Castro F, Baraldi C, Ferrari A. Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review. Expert Opin Investig Drugs. 2020;29:1269\u201375.","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-022-01070-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-022-01070-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-022-01070-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T22:16:12Z","timestamp":1727648172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-022-01070-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1070"],"URL":"https:\/\/doi.org\/10.1007\/s11916-022-01070-6","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"20 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"STC declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. JWW has received honoraria (as a speaker) from Biogen-Idec and Eli Lilly. He has received travel reimbursement and honoraria from American Academy of Neurology, International Headache Society, and Taiwan Headache Society.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}